Medovex Corporation to Present at Rodman & Renshaw 17th Annual Global Investment Conference

ATLANTA, GA -- (Marketwired) -- 08/24/15 -- Medovex Corp. (NASDAQ: MDVX), a developer of medical technology products, today announced that the Company will be presenting at the Rodman & Renshaw 17th Annual Global Investment Conference in New York City on Thursday, September 10, 2015 at 1:45 p.m. EDT.

The presentation will also be available via a live webcast. To access webcast, please click on the following link: The webcast replay will remain available for 90 days following the live presentation.

Mr. Jarret Gorlin, CEO, and Mr. Patrick Kullmann, President and COO, will be providing updates on the company's patented DenerveX™ System, which is intended to treat Facet Joint Syndrome (FJS) and their Streamline® IV Suspension System (ISS), a patient equipment management device that makes the transport of patients and their equipment within hospitals safe and efficient.

The Rodman & Renshaw 17th Annual Global Investment Conference includes over 200 public and private companies presenting their businesses to an audience of approximately 2,000 attendees. With tracks dedicated to Healthcare, Metals & Mining, Technology, Cleantech and Growth, this year's conference will bring presenting companies together with a vast audience of financial and strategic investors. In addition to corporate presentations, Rodman facilitates one-on-one investor meetings and provides platforms for engaged Q&A sessions. Rodman & Renshaw is proud to donate a portion of proceeds from this year's event to New York University's Center for Neural Science.

If you are an institutional investor, and would like to attend the Medovex presentation, please click on the following link to register for the Rodman & Renshaw conference. Once your registration is confirmed, you will be prompted to log into the conference website to request a one-on-one meeting with management.

About Medovex

Medovex was formed to acquire and develop a diversified portfolio of potentially ground breaking medical technology products. Criteria for selection include those products with potential for significant improvement in the quality of patient care combined with cost effectiveness. The Company's first pipeline product, the DenerveX device, is intended to provide long lasting relief from pain associated with facet joint syndrome at significantly less cost than currently available options. To learn more about Medovex Corp., visit The DenerveX System is not commercially available.

Safe Harbor Statement

Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company's filings with the Securities and Exchange Commission (the "SEC"), not limited to Risk Factors relating to its patent business contained therein. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.


Medovex Corp.
Jason Assad
Email Contact

Source: Medovex Corporation